Is Vorinostat a targeted drug?

Vorinostat (Vorinostat) is a hydroxymethyl HDAC inhibitor targeting class I, II and IV HDACs. Oral doses of 400 mg/d were well tolerated and resulted in significant increases in acetylation biomarkers in peripheral blood mononuclear cells (PBMCs). In 2006, vorinostat was approved as a treatment for patients with relapsed, progressive, or persistent cutaneous T-cell lymphoma (CTCL) who have received at least two systemic therapies.

Early-stage clinical trials in patients with a variety of solid and hematologic malignancies have shown that vorinostat is generally well tolerated, whether administered intravenously or orally. Although well tolerated, vorinostat as a single agent has not been shown to be effective in AML and diffuse large B-cell lymphoma (DLBCL). Nonetheless, vorinostat has been shown to enhance the antitumor activity of conventional and investigational drugs in hematological malignancies. A phase II trial of vorinostat, idarubicin, and cytarabine in patients with AML or MDS showed an overall objective response rate of 85%, with 76% achieving a complete response and 9% achieving a complete response with incomplete platelet recovery.

The original drug of vorinostat is not currently on the market in China, and therefore cannot be included in the national medical insurance coverage. Overseas, there is an American version of the original drug, specifications100mg*120 pills per box, which may cost around 100,000 yuan (the price may fluctuate due to exchange rate effects). It is very expensive, and there is currently no generic version of vorinostat produced and launched. For more drug information and specific prices, please consult a medical consultant.